UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 5, 2020 (July 30, 2020)

 

MARIZYME, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-27237

 

82-5464863

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

225 Chimney Corner Lane, Suite 2001, Jupiter Florida

 

33458

(Address of principal executive offices)

 

(Zip Code)

 

(732) 723-7395

(Registrant’s telephone number, including area code)

 

109 Ambersweet Way, #401 Davenport, Florida 33897

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging Growth Company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

[   ]

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Not applicable.

 

 

 

 

 


 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Acquisition

 

As previously disclosed by Marizyme, Inc. (the “Company”) in its Current Report on Form 8-K filed with the Commission on December 19, 2019, on December 15, 2019, the Company entered into an asset purchase agreement, as amended on March 31, 2020 and May 29, 2020 (the “Agreement”), with Somahlution, LLC, Somahlution, Inc. and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah”) to acquire all of the assets, and none of the liabilities, of Somah (the “Acquisition”). Somah is engaged in developing products to prevent ischemic injury to organs and tissues and its products (the “Somah Products”) include DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties.

 

On July 30, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the manufacture under Somahlution, Inc. of CE marked products for sale in the EU.

 

Private Placement

 

On August 3, 2020, the Company conducted an initial closing of a private placement (the “Private Placement”) pursuant to subscription agreements (the “Subscription Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company sold and issued to the Investors an aggregate of 4,609,984 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.25 per Share for an aggregate amount of $5,762,480. As required by the Subscription Agreements, at the closing, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Investors are entitled to certain “piggy back” registration rights.

 

A FINRA registered broker dealer acted as placement agent with respect to the Private Placement and will receive a cash fee of $460,000 from the sale of the Shares to the Investors and warrants to purchase 229,499 shares of Common Stock.

 

The securities offered have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

The information contained in Item 1.01 above with respect to the Acquisition is incorporated by reference in response to this Item 2.01.

 

On July 30, 2020, the Company closed the Acquisition. Prior to the closing of the Acquisition, there was no material relationship between Somah or any of its owners and the Company.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information contained in Item 1.01 above is incorporated by reference in response to this Item 3.02.

 

Each of the Investors in the Private Placement is an “accredited investor” as that term is defined in Regulation D, Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”). The Shares issued and sold in the Private Placement were offered and sold by the Company in reliance on an exemption from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506(b) of Regulation D thereunder. In connection with the sale of the Shares, the Company relied on the Investors' written representations that they were each an "accredited investor" as defined in Rule 501(a) of Regulation D. In addition, neither the Company nor anyone acting on its behalf has offered or sold the Shares by any form of general solicitation or general advertising.


 

 

Item 9.01 Financial Statement and Exhibits

 

(d) Exhibits

 

The following exhibits are filed herewith:

 

Exhibit No.

 

Description of Exhibit

10.1

 

Amendment No. 3 dated July 30, 2020 to Asset Purchase Agreement dated December 15, 2020.

 

[Signature page follows]


 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Marizyme, Inc. has duly caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 5, 2020

MARIZYME, INC.

 

 

 

 

By:

/s/ Nicholas P. DeVito

 

 

Nicholas P. DeVito

 

 

Interim Chief Executive Officer

 

 

AMENDMENT NO. 3

TO

ASSET PURCHASE AGREEMENT DATED DECEMBER 15, 2019

 

This AMENDMENT NO. 3 TO ASSET PURCHASE AGREEMENT DATED DECEMBER 15, 2020 (this “Amendment”) is made and entered into as of July 30, 2020, by and among Somahlution, LLC, Somahlution, Inc. and Somaceutica, LLC, companies incorporated or organized under the laws of the State of Delaware (collectively, the “Somah Entities”), and Marizyme, Inc., a Nevada corporation (the “Buyer”).

 

RECITALS:

 

A.The Somah Entities and Buyer entered into that certain Asset Purchase Agreement dated December 15, 2019, as amended on March 31, 2020, and further amended on May 29, 2020 (the “Agreement”), pursuant to which the Somah Entities agreed to sell the Assets to the Buyer. Capitalized terms used herein but which are not otherwise defined shall have the meanings given to such terms in the Agreement. 

 

B.To comply with certain European Union regulatory requirements, the Somah Entities and Buyer wish to further amend the Agreement to, among other things, include in the definition of “Assets” all of the outstanding capital stock of Somahlution, Inc.  

 

AGREEMENT:

 

In consideration of the foregoing recitals and the respective covenants, agreements, representations and warranties contained herein and in the Agreement, the parties, intending to be legally bound, agree to amend and supplement the Agreement as follows:

 

1.Capital Stock of Somahlution, Inc.  

 

(a)Definitions. The term “Assets,” as defined in the Agreement, shall also include all of the outstanding capital stock (the “Shares”) of Somahlution, Inc. 

 

(b)Closing Deliverables. In addition to the Somah Entities’ Closing deliverable obligations set forth in Section 6(c) of the Agreement, at the Closing, Somahlution, LLC shall deliver to the Buyer a certificate or certificates representing the Shares, duly endorsed or accompanied by stock powers duly endorsed in blank. 

 

(c)Representations and Warranties. In addition to the representations and warranties of the Somah Entities set forth in Section 4 of the Agreement, Somahlution, LLC represents and warrants to the Buyer as follows: 

 

(i)Somahlution, LLC holds of record and owns beneficially all of the Shares, being all of the issued and outstanding shares of capital stock of Somahlution, Inc., free and clear of all encumbrances, liens, security interests, and rights of first refusal, negotiation or offer;  

 

(ii)Somahlution, LLC has the power and authority to execute, deliver and perform its obligations under this Amendment and to sell, assign, transfer and deliver to the Buyer the Shares as contemplated hereby; and 

 

(iii)Somahlution, LLC is not party to any contract obligating the Seller to vote or dispose of any shares of the capital stock of, or other equity or voting interests in, Somahlution, Inc. 

 

(d)Conditions to Closing. In addition to the Conditions to Closing set forth in Section 3 of the Agreement, the obligations of the Buyer to consummate the Acquisition are subject to the following: 

 

(i)The representations and warranties set forth in Section 1(c) above shall be true and correct in all material respects at and as of the Closing Date; 

 

(ii)Somahlution, LLC shall have delivered to the Buyer a certificate to the effect that, as of the Closing, Somahlution, Inc, has no liabilities; and 

 

(iii)Somahlution, LLC shall deliver to the Buyer confirmation that Somahlution, Inc. is in Good Standing in Florida. 


 

 

(e)Post-Closing Covenant. Somahlution, LLC shall be responsible for any and all costs incurred relating to the legal action known as Patsnap (UK) Ltd. vs. Somahlution, Inc., whether relating to a settlement, court costs or legal fees, incurred prior to or after the Closing.  

 

(f)Indemnification. The indemnification provisions of Section 8 of the Agreement shall apply to the representations, warranties, covenants and agreements set forth in this Section 1 of the Amendment and shall survive the Closing until twenty-four (24) months after the Closing Date. 

 

2. Effect of Amendment. Except as amended by this Amendment, the Agreement shall remain in full force and effect. In addition, if there are any inconsistencies between the Agreement and this Amendment, the terms of this Amendment shall prevail and control for all purposes. 

 

3. Governing Law. This Amendment shall be construed in accordance with and governed by the Laws of the State of New York without giving effect to the principles of conflict of laws. 

 

4. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original regardless of the date of its execution and delivery. All such counterparts together shall constitute one and the same instrument. 

 

[Signature page follows.]


 

 

IN WITNESS WHEREOF, the Parties have duly executed this Amendment as of the date first written above.

 

SOMAHLUTION, LLC

 

By:

/s/ Satish Chandran

Name:

Satish Chandran

Title:

Chief Executive Officer

 

SOMAHLUTION, INC.

 

By:

/s/ Satish Chandran

Name:

Satish Chandran

Title:

Chief Executive Officer

 

SOMACEUTICA, LLC

 

By:

/s/ Satish Chandran

Name:

Satish Chandran

Title:

Chief Executive Officer

 

MARIZYME, INC.

 

By:

/s/ Nicholas DeVito

Name:

Nicholas Devito

Title:

Interim Chief Executive Officer